Regulators signal caution on epigenetic clocks as trial endpoints
Companies want to prove longevity drugs work by showing a blood test says you got biologically younger. Regulators have said that is not enough on its own — they still want to see people actually doing better. This makes longevity trials slower and more expensive.
What happened
The workshop reviewed evidence for methylation clocks as surrogate endpoints across 14 candidate trials.
Reviewers concluded correlation with outcomes is insufficient to establish surrogate validity.
Clocks were endorsed as supportive mechanistic measures and for trial enrichment.
Why it matters
Without an accepted surrogate endpoint, longevity trials must measure disease or function, which takes years and large samples.
This directly affects the cost structure of every clinical-stage geroscience company.
It also reduces the risk of a wave of approvals based on biomarker movement alone.
Evidence check
Optional scientific context: how much weight this finding can carry.
- A position summary is not binding regulation.
- Applies principally to one regulatory jurisdiction.
- Does not preclude future acceptance as evidence accumulates.
LONGEFI Signal
LONGEFI's deterministic scientific synthesis — not a market view.
How strong the underlying evidence is.
How new or meaningfully different the finding is.
How close the evidence is to meaningful human application.
How likely this is to matter commercially or strategically.
LONGEFI Signal is a 0–100 comparison score across scientific evidence, novelty, human relevance and market relevance. It is not an investment rating and not a prediction of investment performance.LONGEFI Signal is a 0–100 comparison score built from four analytical dimensions — scientific evidence, novelty, human relevance and market relevance — so developments can be ranked against each other. NOT AN INVESTMENT RATING: it is not a prediction of investment performance and not a view on any security.
Science explained
The terminology, in plain language.
- Surrogate endpoint
- A short-term measurement used as a stand-in for the outcome you actually care about.
- Methylation clock
- A blood test estimating biological age from chemical tags on DNA.
- Trial enrichment
- Using a test to select participants most likely to show an effect.
- Validation
- Proving that changing the measurement reliably changes the real outcome.
What would change our view?
The findings that would raise or lower this Signal.
Formal guidance
The position codified in published regulatory guidance rather than workshop consensus.
Qualified biomarker
A specific clock achieving formal biomarker qualification for a defined context of use.
Sources & traceability
Supporting documents, underlying datasets and independent sources are not the same thing.
- Workshop summary
Nature Biotechnology
Everything below is commercial interpretation. It does not form part of the LONGEFI Scientific Signal.
Companies & assets
Exposure to the technology discussed, not an investment view.
Life Biosciences
PrivateThis development may be relevant to this company’s longevity programs.
Partial epigenetic reprogramming (OSK)
Starting in the eye contains delivery and safety risk while still testing the core rejuvenation hypothesis in humans.
Altos Labs
PrivateThis development may be relevant to this company’s longevity programs.
Cellular reprogramming
If cellular age can be partially reset without loss of cell identity, a single platform could address several age-related diseases instead of one indication at a time.
Veri Metabolic
VRMBThis development may be relevant to this company’s longevity programs.
Metabolic health measurement and therapeutics
Metabolic dysfunction is the earliest measurable driver of age-related disease, making it the most commercially tractable entry point.
Market implications
Which parts of the field this touches, and over what horizon.
Life Biosciences
Potentially challengedClinical programmes that had positioned clock measures as supportive endpoints.
Trials will need harder functional or clinical endpoints, extending timelines and cost.
Altos Labs
Long-term relevancePreclinical rejuvenation research using epigenetic age measures.
No immediate effect, but eventual trial design must anticipate the stricter endpoint standard.
Veri Metabolic
Sector signalConsumer and clinical biological-age measurement.
Diagnostics use is largely unaffected; the restriction applies to efficacy claims in trials.
- Epigenetic clocks
- Biomarker validation
- Trial design
- Geroscience biotech
- Diagnostics
- Clinical research organisations
Immediate relevance to trial planning and clinical-stage budgets. Diagnostics companies selling clock-based consumer tests are unaffected regulatorily but face reputational read-through.
LONGEFI does not issue buy, sell or hold recommendations, and nothing here is personalized financial advice.
Trend connections
How this connects to themes LONGEFI tracks over time.
This is the first development LONGEFI has logged in this theme.